ArticleCancer immunology, immunotherapy : CII2012

Intravenous and intradermal TriMix-dendritic cell therapy results in a broad T-cell response and durable tumor response in a chemorefractory stage IV-M1c melanoma patient.

An M T Van Nuffel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.